Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IL-1R8 is a checkpoint in NK cells regulating anti-tumor and anti-viral activity

ABSTRACT: IL-1R8 is a checkpoint in NK cells regulating anti-tumor and anti-viral activity

PROVIDER: PRJNA416792 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6243280.fastq.gz	Fastqsanger.gz
	SRR6243290.fastq.gz	Fastqsanger.gz
	SRR6243300.fastq.gz	Fastqsanger.gz
	SRR6243310.fastq.gz	Fastqsanger.gz
	SRR6243271.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

IL-1R8 is a checkpoint in NK cells regulating anti-tumor and anti-viral activity

Project description:We reported that IL-1R8 serves as a checkpoint for NK cell maturation and effector functions. Its genetic blockade unleashes NK-cell mediated resistance to hepatic carcinogenesis, hematogenous liver and lung metastasis and cytomegalovirus infection.

2017-11-02 | GSE105043 | GEO

IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity.

Project description:Interleukin-1 receptor 8 (IL-1R8, also known as single immunoglobulin IL-1R-related receptor, SIGIRR, or TIR8) is a member of the IL-1 receptor (ILR) family with distinct structural and functional characteristics, acting as a negative regulator of ILR and Toll-like receptor (TLR) downstream signalling pathways and inflammation. Natural killer (NK) cells are innate lymphoid cells which mediate resistance against pathogens and contribute to the activation and orientation of adaptive immune responses. NK cells mediate resistance against haematopoietic neoplasms but are generally considered to play a minor role in solid tumour carcinogenesis. Here we report that IL-1R8 serves as a checkpoint for NK cell maturation and effector function. Its genetic blockade unleashes NK-cell-mediated resistance to hepatic carcinogenesis, haematogenous liver and lung metastasis, and cytomegalovirus infection.

| S-EPMC5768243 | biostudies-literature

CREM is a regulatory checkpoint of CAR and IL-15 signaling in NK cells

Project description:This is a preclinical study investigating the role of CREM transcription factor in CAR NK cells. We found thata CREM is a regulatory checkpoint induced by CAR CD3z signaling and IL-15 stimulation that leads to suppression of NK cell function. CREM KO enhances the anti-tumor efficacy of CAR NK cells.

2025-03-14 | GSE267523 | GEO

The RNA m6A reader YTHDF2 controls NK cell anti-tumor and anti-viral immunity

Project description:N6-methyladenosine (m6A) is the most prevalent post-transcriptional modification on RNA. NK cells are the predominant innate lymphoid cells that mediate anti-viral and anti-tumor immunity. However, whether and how m6A modifications affect NK cell immunity remains unknown. Here, we discover that YTHDF2, a well-known m6A reader, is upregulated in NK cells upon activation by cytokines, tumors, and cytomegalovirus infection. Ythdf2 deficiency in NK cells impairs NK cell anti-tumor and anti-viral activity in vivo. YTHDF2 maintains NK cell homeostasis and terminal maturation, correlating with modulating NK cell trafficking and regulating Eomes, respectively. YTHDF2 promotes NK cell effector function and is required for IL-15-mediated NK cell survival and proliferation by forming a STAT5-YTHDF2 positive feedback loop. Transcriptome-wide screening identifies Tardbp to be involved in cell proliferation or survival as a YTHDF2-binding target in NK cells. Collectively, we elucidate the biological roles of m6A modifications in NK cells and highlight a new direction to harness NK cell anti-tumor immunity.

2021-05-08 | GSE174027 | GEO

Identification of B-cell specific checkpoint molecules regulating anti-tumor immunity

Project description:Identification of B-cell specific checkpoint molecules regulating anti-tumor immunity

| PRJNA937214 | ENA

Effect of anti-IL-15 administration on T cell and NK cell homeostasis in rhesus macaques (TCM)

Project description:Analysis of the effect of anti-IL-15 monoclonal antibody treatment on T cell and NK cell homeostasis in rhesus macaques. The hypothesis tested in the present study was that repeated administrations of a rhesusized anti-IL-15 monoclonal antibody would block IL-15 activity in vivo and result in changes to T and/or NK cell population dynamics that would reflect physiologic IL-15 function. The results provide important information on the specific role IL-15 plays in effector memory T cell and NK cell homeostasis, noting that effector memory T cells but not NK cells can be maintained in the absence of IL-15 signaling by the activity of other cytokines. Sort-purified CD8+ and CD4+ TCM from PBMC, before and after treatment with IgG1 Ab and anti-IL15 Ab

2016-09-07 | E-GEOD-76785 | biostudies-arrayexpress

Effect of anti-IL-15 administration on T cell and NK cell homeostasis in rhesus macaques (TEM)

Project description:Analysis of the effect of anti-IL-15 monoclonal antibody treatment on T cell and NK cell homeostasis in rhesus macaques. The hypothesis tested in the present study was that repeated administrations of a rhesusized anti-IL-15 monoclonal antibody would block IL-15 activity in vivo and result in changes to T and/or NK cell population dynamics that would reflect physiologic IL-15 function. The results provide important information on the specific role IL-15 plays in effector memory T cell and NK cell homeostasis, noting that effector memory T cells but not NK cells can be maintained in the absence of IL-15 signaling by the activity of other cytokines. Sort-purified CD8+ TEM from PBMC, before and after treatment with IgG1 Ab and anti-IL15 Ab

2016-09-07 | E-GEOD-76796 | biostudies-arrayexpress

Bulk RNA-seq for B-cell specific checkpoint molecules regulating anti-tumor immunity

Project description:Bulk RNA-seq for B-cell specific checkpoint molecules regulating anti-tumor immunity

| PRJNA937162 | ENA

IL-2/IL-15 signaling induces NK cell production of FLT3LG which augments anti-PD-1 immunotherapy

Project description:Natural killer (NK) cells play a critical role in anti-cancer immunity through their direct cytotoxicity and production of cytokines, such as Flt3L. NK cell production of Flt3L controls conventional type I dendritic cell (cDC1) abundance in the tumor and promotes protective immune responses. Here, we show that NK cell production of Flt3l in the tumor is regulated by activation, and that activation by IL-2 and IL-15 uniquely induces Flt3L expression in NK cells. IL-2 signaling in NK cells leads to more Flt3L production, increased cDC1 abundance in the tumor, and increased activity of anti-PD-1 immunotherapy in melanoma. Further, NK cell subsets differentially regulate Flt3L in the tumor, with CD11b–CD27+ NK cells in mouse tumors enriched for IL-2-family signaling and upregulating Flt3l upon activation. Further, human CD56brightCD16– NK cells more strongly correlate with cDC1 and FLT3LG levels than other NK cell subsets across multiple human melanoma datasets and cancer indications. This mechanistic insight into NK cell regulation of FLT3LG and control of the NK cell-cDC1 axis provides insights and novel strategies for the development of more effective cancer immunotherapies.

2025-09-23 | GSE282979 | GEO

Targeting ERAP enhances anti-tumor immunity by disrupting the NKG2A/HLA-E inhibitory checkpoint

Project description:New targets that enhance anti-tumor immunity must be identified to improve the efficacy of cancer immunotherapy. Here we show that loss of endoplasmic reticulum aminopeptidase (ERAP) family proteins improves anti-tumor immunity and synergizes with immune checkpoint blockade. Mechanistically, we show that loss of ERAP inactivates the HLA-E/NKG2A checkpoint, which normally restrains tumor killing by both CD8+ T cells and NK cells. The inhibitory activity of HLA-E is dependent on its presentation of a restricted set of invariant epitopes which form the binding surface for the NKG2A/CD94 receptor complex. Using genetic screening, in vivo models, cell-based assays, and immunopeptidomics, we show that loss of ERAP activity prevents the processing of these invariant peptides and alters the presented peptidome of both HLA-E and classical MHC-I. HLA-E neo-peptides presented after ERAP deletion are unable to bind the NKG2A/CD94 receptor, rendering tumor cells highly susceptible to killing by NKG2A+ cytotoxic T and NK cells. Thus, loss of ERAP phenocopies the loss or inhibition of the HLA-E/NKG2A pathway and represents an attractive therapeutic approach to inhibit this critical checkpoint. More broadly, this work identifies ERAP1/2 as druggable intracellular enzymes that could be targeted using small molecules to inactivate a cell-surface inhibitory pathway and represents a novel approach to therapeutic modulation of immune responses.

2024-11-21 | PXD052031 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data